cyc 202 has been researched along with indirubin-3'-monoxime in 11 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (indirubin-3'-monoxime) | Trials (indirubin-3'-monoxime) | Recent Studies (post-2010) (indirubin-3'-monoxime) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 139 | 0 | 82 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhattacharjee, AK; Ellis, W; Gerena, L; Geyer, JA; Kathcart, AK; Kyle, DE; Li, Z; Lopez-Sanchez, M; Nichols, DA; Prigge, ST; Terrell, J; Waters, NC; Woodard, CL | 1 |
| Crovace, C; Mapelli, M; Massimiliano, L; Meijer, L; Musacchio, A; Seeliger, MA; Tsai, LH | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bravo-Altamirano, K; DeStefino, NR; Liang, M; Mazzarisi, CM; Meriney, SD; Olszewski, RA; Rensch, G; Swanson, L; Tarr, TB; Valdomir, G; Wilson, GM; Wipf, P | 1 |
| Chen, CY; Cheng, JJ; Chiou, CT; Lee, WC; Li, WT; Liao, JH; Lin, LC; Shia, KS; Song, JS; Wu, MH | 1 |
| Cheng, X; Christ, J; Eisenbrand, G; Merz, KH; Muehlbeyer, S; Thommet, A; Vatter, S; Wölfl, S; Zeller, J | 1 |
| Bamba, D; Davis, C; Gallo, RC; Gwarzo, MY; Heredia, A; Le, N; Redfield, RR; Sadowska, M | 1 |
| Lim, KM; Tan, VB; Tay, TE; Zhang, B; Zhuang, S | 1 |
11 other study(ies) available for cyc 202 and indirubin-3'-monoxime
| Article | Year |
|---|---|
Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases.
Topics: Amino Acid Sequence; Animals; Antimalarials; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Enzyme Inhibitors; Humans; Indoles; Models, Molecular; Molecular Sequence Data; Plasmodium falciparum; Structure-Activity Relationship | 2003 |
Mechanism of CDK5/p25 binding by CDK inhibitors.
Topics: Crystallography, X-Ray; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Indoles; Models, Molecular; Molecular Conformation; Nerve Tissue Proteins; Oximes; Protein Binding; Purines; Roscovitine; Stereoisomerism | 2005 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Synthesis and biological evaluation of a selective N- and p/q-type calcium channel agonist.
Topics: | 2012 |
Synthesis and evaluation of 3-ylideneoxindole acetamides as potent anticancer agents.
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Indoles; Mice; Mice, Inbred BALB C; Models, Molecular; Xenograft Model Antitumor Assays | 2015 |
Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Screening Assays, Antitumor; Humans; Indoles; Oximes; Protein Kinase Inhibitors; Receptor, IGF Type 1; Signal Transduction; Solubility; Structure-Activity Relationship | 2017 |
Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication.
Topics: Cyclin-Dependent Kinases; Drug Evaluation; Flavonoids; HIV-1; Humans; Indoles; Inhibitory Concentration 50; Leukocytes, Mononuclear; Macrophages; Oximes; Piperidines; Positive Transcriptional Elongation Factor B; Protein Kinase Inhibitors; Purines; Reverse Transcriptase Polymerase Chain Reaction; Roscovitine; U937 Cells; Virus Replication | 2005 |
Study of the inhibition of cyclin-dependent kinases with roscovitine and indirubin-3'-oxime from molecular dynamics simulations.
Topics: Binding Sites; Computer Simulation; Cyclin-Dependent Kinases; Humans; Hydrogen Bonding; Indoles; Models, Chemical; Models, Molecular; Oximes; Protein Binding; Protein Kinase Inhibitors; Purines; Roscovitine; Software; Static Electricity; Thermodynamics; Water | 2007 |